

Supplementary Table 1. Changes in anti-parkinsonian medications between baseline and 12 months after surgery for DBS

	GPI DBS (<i>n</i> = 14)		STN DBS (<i>n</i> = 28)		At baseline–at 12 months		
	At baseline	At 12 months	At baseline	At 12 months	GPI DBS (<i>n</i> = 14)	STN DBS (<i>n</i> = 28)	<i>p</i> value
LED							
<i>n</i> (%)	14 (100.0)	14 (100.0)	28 (100.0)	28 (100.0)			
mg (mean ± SD)	1317.2 ± 382.3	1260.2 ± 261.6	1268.1 ± 468.1	830.6 ± 331.4	57.0 ± 219.2	437.5 ± 483.6	0.004*
Levodopa							
<i>n</i> (%)	14 (100.0)	14 (100.0)	28 (100.0)	28 (100.0)			
mg (mean ± SD)	764.3 ± 268.7	780.4 ± 190.7	886.6 ± 361.9	562.5 ± 277.5	-16.1 ± 145.0	324.1 ± 325.8	< 0.001*
Ropinirole							
<i>n</i> (%)	7 (50.0)	6 (42.9)	15 (53.6)	13 (46.4)			
mg (mean ± SD)	3.3 ± 4.3	2.7 ± 4.0	4.7 ± 5.9	3.0 ± 3.9	0.6 ± 1.8	1.7 ± 5.1	0.507
Pramipexole							
<i>n</i> (%)	6 (42.9)	7 (50.0)	7 (25.0)	11 (39.3)			
mg (mean ± SD)	0.9 ± 1.1	0.7 ± 1.1	0.5 ± 1.0	0.6 ± 0.8	0.1 ± 0.7	-0.2 ± 1.0	0.189
Pergolide							
<i>n</i> (%)	0 (0.0)	0 (0.0)	4 (14.3)	0 (0.0)			
mg (mean ± SD)	0.0 ± 0.0	0.0 ± 0.0	0.3 ± 0.6	0.0 ± 0.0	0.0 ± 0.0	0.2 ± 0.5	0.142
Amantadine							
<i>n</i> (%)	13 (92.9)	11 (78.6)	19 (67.9)	16 (57.1)			
mg (mean ± SD)	210.7 ± 83.6	160.7 ± 100.3	146.4 ± 109.7	108.9 ± 101.9	50.0 ± 107.4	37.5 ± 108.5	0.861
MAO-B inhibitor							
<i>n</i> (%)	1 (7.1)	1 (7.1)	5 (17.9)	3 (10.7)			
mg (mean ± SD)	0.7 ± 2.7	0.4 ± 1.3	1.6 ± 3.6	0.7 ± 2.2	0.4 ± 1.3	0.9 ± 4.1	0.711

**p* value < 0.05. GPI: globus pallidus interna, STN: subthalamic nucleus, DBS: deep brain stimulation, LED: levodopa equivalent dose, MAO-B: monoamine oxidase-B, SD: standard deviation.